Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 1.225 2,410,236 13:07:34
Bid Price Offer Price High Price Low Price Open Price
1.15 1.30 1.275 1.225 1.225
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.56 -1.13 -0.29 7
Last Trade Time Trade Type Trade Size Trade Price Currency
13:05:51 O 50,000 1.20 GBX

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Discussions and Chat

Feedback Forums and Chat

Date Time Title Posts
02/6/202013:54FEEDBACK plc Medical Imaging Technology5,631
04/11/201907:39Feedback 35
01/11/201815:33****Feedback PLC****3,006
03/2/201011:50Feedback looks interesting - could easily be a ten bagger over next year396
03/9/200211:53ainsley long .........................quick shart it2

Add a New Thread

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:05:511.2050,000600.01O
11:47:101.2063,291759.56O
11:41:591.2088,0401,060.44O
11:41:371.2084,0151,011.96O
11:37:371.22100,1751,217.14O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
02/6/2020
09:20
Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 1.23p.
Feedback Plc has a 4 week average price of 0.83p and a 12 week average price of 0.35p.
The 1 year high share price is 2.10p while the 1 year low share price is currently 0.35p.
There are currently 539,949,917 shares in issue and the average daily traded volume is 2,273,152 shares. The market capitalisation of Feedback Plc is £6,884,361.44.
11/5/2020
17:29
yump: Don't worry, increasing use in the NHS hopefully doesn't depend on the powers that be watching TV, although the share price might depend on publicity. Which one do people want ? That's the clue to where the share price will go.
27/4/2020
01:12
bunz3: not good for the day traders from when share was over one pound try to deramp have most people at ncyt listend to them them don't think so looking at share price looking at number of buys last week even no don't don't think so have people done their own research read rns , even though buyers not listening to derampers /day traders they have given up even spending their time day and night ,weekends /day and night they trying so hard YET THEY FAILING so good of progress at ncyt so good of rns released at ncyt now that ncyt now manufacturing 4 MILLION COVID 19 TESTING KITS PER MONTH more buyers loading waiting for even more good rns will the next number of weeks see the share price start to move up TO A SHARE PRICE TO MATCH THE PROGRESS BY NCYT
24/4/2020
08:42
meganxmas: White dont think that puts a cap on the price in any way. Think it aligns everyone (from this point ... I accept that many bought long ago at far higher amounts). Recipients have to buy them and only benefit when share price is above (hopefully very well above) 1.2p. I prefer more onerous hurdles but am quite happy to see everyone aligned to the same goal of share price appreciation.
16/4/2020
21:36
yump: I can count at least 10 proactive videos on ORPH and only 1 from FDBK since last September. Thank God. imo proactive brown-noser 'interviews' full of pathetic platitudes are a contra-indicator. Hopefully FDBK is not run by financial bods just aiming to get the share price up.
29/3/2020
20:41
lr2: Https://ukinvestormagazine.co.uk/feedback-offers-bleepa-for-covid-19-use/ Feedback offers Bleepa for COVID-19 use By Andrew Hore - 29/03/2020 Feedback (LON: FDBK) is offering its Bleepa medical imaging communications platform to help with COVID-19. Hospitals will be able to use it for free. Bleepa was launched last July. It can be used to transmit encrypted data between a hospital and a clinician’s own device when they are away from the hospital. Images, such as x-rays, CT scans and ultrasound scans can be sent. In the case of COVID-19, images of the lungs of patients can be transmitted. The image quality means that important decisions can be made from these images. Bleepa uses Feedback’s Cadran picture archiving and communications system. There is also an encrypted messaging function. Bleepa is the main focus for Feedback and it offers the potential for significant recurring revenues. AIM-quoted Feedback secured the first pilot study for Bleepa with The Pennine Acute Hospitals NHS Trust, which has been using Bleepa for respiratory requests. This pilot was near to completion, but it has been suspended for the time being. Self-isolation One of the attractions of Bleepa is that it can be used by clinicians that are self-isolating. They can continue to help with diagnosis. The whole team can be in different locations and still be able to work together. There has been a significant increase in chest x-rays and CT scans. These can be assessed via Bleepa and there is no concern about security. This will help to make clinicians aware of the effectiveness of Bleepa and how it can be helpful at any time. The Feedback share price has been highly volatile. There was a jump in the share price, but it fell back to 0.65p.
26/3/2020
23:14
dave4545: Well the Rns did say no money or for free. So if any company gives something for free normally it's not going to affect the share price but mentions c-19 in anything now and spike If FDBK raise money on this it will be very naughty but I think they still have around £1 mil of cash... I'd not feel sorry for the mm's, they are making millions a day with crazy spreads and 2 way trade atm
29/9/2019
15:12
ged5: On Friday there were 12 companies that hadn't issued an RNS but rose by 10% or more. I have listed them here with the NOMAD (except DKE where it's the broker) and the approximate time of the rise ALTN VSA Capital up most of day but after 2:00 CLON Strand Hanson up from 2:00 CGNR Allenby Capital up just before 4:00 LME Cairn Financial Advisors but have Peterhouse as broker Before 10:00 AXM Cairn Financial Advisors before 10:00 Had an announcement on 25-9-19 CIP Strand Hanson Limited up over 20% just after 11:00 NET FinnCap Limited up about 10% about 1:30 Had an announcement 25-9-19 INTO No available information PHD Finncap Limited up over 10% just after 11:00 FLX Stifel Nicolaus Europe Limited, Nomad and Joint Broker up just over 10% at 9:00 DKE Peterhouse Capital Up about 10% just after 2:00 So there were other companies with more than 10% rises but no "speeding ticket" There were some when the rise was early enough to give a statement. So was the Nomad correct in making the Statement re share price? Technically they should all have done. So why FDBK? Conspiracy theories about the company or Nomad to try to suppress the SP? It just didn't make sense to me. I think this is culprit: tradinstock ‏ @TradeInStock247 Sep 27 #FDBK #IQAI mkt not getting it yet they use our techno -Texrad technology that is used by StONECHECKER of IQAI.This has just been FDA hxxp://approved.In other words Texrad has actually been FDA approved by default today! rns later or MONDAY IT IS WRONG TO MAKE MISLEADING/INCORRECT COMMENTS TO INFLUENCE THE SHARE PRICE That tweet was clearly wrong and misleading. Any comments?
15/8/2019
21:17
lr2: Megan, 1. If the full £2 million was placed why did the placing note say "The Company has received letters of subscription for, in aggregate, 57,700,000 Subscription Shares." A fully subscribed placing would have resulted in 166,666,667 Subscription Shares having been taken up on the day. Maybe they have now but they hadn't then. 2. If you were happy to subscribe at 1.5p, the question you should be asking is why couldn't the company raise £2 million at that price. The company only thought 1.2p a share was worth trying to get. Perhaps that's all they think a share is really worth at present. Not wrong either, that's exactly where the price is today. 3. If the leak wasn't planned then it was an astonishing coincidence that the "Placing and the Subscription will result in the issue of a total of 166,666,667 New Ordinary Shares, representing, in aggregate, approximately 30.87 per cent. of the Enlarged Share Capital." The Placing Price represents a true discount of approximately 31.42% to the closing mid-market price of 1.75 pence per Ordinary Share on the day before the placing was leaked. (The last day the share price didn't decline before the placing was announced.) 30.78% vs. 31.42% is close enough in my eyes to tell me that the placing was almost certainly leaked and that the share price was pushed down to the appropriate level to facilitate it. The markets knew precisely what was going on and the board didn't have the guts to pull the plug in disgust. They took the easy option and screwed their long term shareholders again. 4. If the company "were very angry about the leak" then why has the status quo remained in place? If the leak came from the board then we should have seen heads rolling. If the leak came from promoters (or their customers) then they should be sacked and replaced. As nothing has happened then I must assume that nobody gives a damn. Good luck with your new holding. I imagine you will be selling as soon as possible so you can take part in some other placing much like the vast majority of people who are about to acquire new shares.
06/6/2019
09:37
kinwah: Times article today on the NHS looking to fast-track new machine learning technologies. At least it has given the FDBK share price a boost.
29/5/2019
18:51
hedgehog 100: From the IQAI thread: LR2 8 May '19 - 20:59 - 136 of 193 " ... Regarding Trevor Brown, I'd never bumped into him before Feedback but when I did I was disgusted at aspects of his behaviour and decided to investigate him. That was enlightening. The main thing I found at that time was him posting both here and elsewhere under two different pseudonyms and what he posted was, I believed, detrimental to Feedback in general and TexRAD in particular. Ironic really when TexRAD was, and still is, the core software component of Stone Checker. ... " LR2, As promised after your postings on the IQAI thread today, I am paying a 'return visit' ... it would be rude not to! Are you aware of the irony of your being 'so disgusted' at someone posing negative comments about a company? So disgusted apparently that you decide to do exactly the same yourself! And under two different pseudonyms (LR2 here, and Elartu on LSE). And your grudge against Trevor Brown seems to be a classic case of 'shooting the messenger for the message'. You don't like the fact that he flagged up some time ago that FDBK had the wrong strategy. Though all the evidence suggests that he was absolutely right. So if you're going to get angry against anyone, surely you should get angry with the FDBK directors who ignored his advice, rather than with TB for giving that advice? Or am I missing something? It's also deeply concerning that you apparently wish that this important information for investors in FDBK should have been suppressed. So let me set out a few home truths about FDBK. Let's make it a round ten, shall we? (Albeit they're probably obvious to many FDBK shareholders here ... how many have I heard say 'it's just not worth me selling now ...'?) - • Public question marks about the company's strategy. • A pitiful 4% sales growth (at its interim stage) after years of trying. • £738K. annualised pre-tax losses at the interim stage. • Those losses will increase with the recruitment drive etc. • Current cash likely to be below £1M., probably enough for about a year. • Little potential short term excitement expected. • No exciting growth story. • Chart in an entrenched downtrend, and generally declining trading volumes. • No recent director share buying, despite the depressed share price, and not being in a close period. • By the end of 2019 FDBK will be in fundraising countdown mode, with one due within months by then. Who would like to predict the price of FDBK's next fundraising? Current share price 0.725p, market cap. £2.71M. Don't be surprised if IQAI's sales in the current year are actually HIGHER than FDBK's. As well as its losses and current market cap. (£1.44M. at 1.2p) being LOWER. And as regards turnover growth rate ... IQAI will just blow FDBK away.
Feedback share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200602 12:56:51